Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
Toshio ShimizuKazuto NishioKazuko SakaiIsamu OkamotoKunio OkamotoMasayuki TakedaMaiko MorishitaKazuhiko NakagawaPublished in: Cancer chemotherapy and pharmacology (2020)
UMIN000031912 at UMIN Clinical Trials Registry (UMIN-CTR).